Toth Financial Advisory Corp Raises Position in Becton, Dickinson and Company $BDX

Key Points

• Toth Financial Advisory increased its Becton, Dickinson and Company position by 65.7% in the third quarter, bringing its holdings to 26,897 shares valued at approximately $4.8 million. Institutional investors collectively own 86.97% of BDX.
• BDX shares recently traded at $181.76, near their 52-week high, after the company reported quarterly EPS of $3.23 and revenue of $4.98 billion, exceeding analyst expectations. Revenue increased 5.4% year over year.
• The company paid a quarterly dividend of $1.05, equivalent to an annualized $4.20 and a 2.3% yield. Analysts maintain a consensus “Hold” rating with an average price target of $185.07, while insiders have sold 6,906 shares over the past three months.

Toth Financial Advisory Corp grew its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 65.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 26,897 shares of the medical instruments supplier's stock after acquiring an additional 10,661 shares during the quarter. Toth Financial Advisory Corp's holdings in Becton, Dickinson and Company were worth $4,815,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Applied Capital LLC FL increased its stake in Becton, Dickinson and Company by 30.3% during the third quarter. Applied Capital LLC FL now owns 4,255 shares of the medical instruments supplier's stock worth $762,000 after acquiring an additional 990 shares during the last quarter. Benedict Financial Advisors Inc. boosted its holdings in shares of Becton, Dickinson and Company by 1.4% in the 3rd quarter. Benedict Financial Advisors Inc. now owns 25,309 shares of the medical instruments supplier's stock worth $4,530,000 after purchasing an additional 352 shares during the period. Legacy Solutions LLC purchased a new position in shares of Becton, Dickinson and Company in the 3rd quarter worth approximately $226,000. Nautilus Advisors LLC increased its position in shares of Becton, Dickinson and Company by 10.7% during the 3rd quarter. Nautilus Advisors LLC now owns 4,041 shares of the medical instruments supplier's stock valued at $723,000 after purchasing an additional 390 shares during the last quarter. Finally, Moody National Bank Trust Division raised its holdings in Becton, Dickinson and Company by 15.7% during the 3rd quarter. Moody National Bank Trust Division now owns 1,739 shares of the medical instruments supplier's stock valued at $311,000 after buying an additional 236 shares during the period. Hedge funds and other institutional investors own 86.97% of the company's stock.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the completion of the sale, the executive vice president owned 19,720 shares of the company's stock, valued at approximately $3,717,022.80. The trade was a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas Polen, Jr. sold 4,152 shares of the business's stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer owned 110,163 shares of the company's stock, valued at $20,380,155. The trade was a 3.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 6,906 shares of company stock valued at $1,265,855. 0.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Trading Up 0.9%

BDX stock traded up $1.60 during midday trading on Thursday, reaching $181.76. The company's stock had a trading volume of 498,678 shares, compared to its average volume of 2,495,309. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $193.07. The firm has a market capitalization of $50.08 billion, a price-to-earnings ratio of 54.76, a PEG ratio of 12.16 and a beta of 0.21. The stock has a fifty day simple moving average of $181.64 and a two-hundred day simple moving average of $162.18. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.14 by $0.09. The firm had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business's revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the firm earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities research analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th were paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date was Wednesday, September 9th. Becton, Dickinson and Company's dividend payout ratio is currently 126.51%.

Analysts Set New Price Targets

A number of analysts recently issued reports on BDX shares. Evercore set a $180.00 price target on Becton, Dickinson and Company in a research report on Monday, July 6th. Royal Bank Of Canada increased their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a "sector perform" rating in a research note on Thursday, August 13th. UBS Group initiated coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They set a "buy" rating and a $190.00 price target for the company. Stifel Nicolaus set a $195.00 price target on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Finally, Weiss Ratings raised shares of Becton, Dickinson and Company from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Monday, September 28th. Seven analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $185.07.

About Becton, Dickinson and Company

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD's Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.